SYNEOS HEALTH UK LIMITED

CytoDyn has dosed the first patient in a Phase II clinical trial evaluating leronlimab, a CCR5 antagonist, in patients with relapsed/refractory microsatellite stable colorectal cancer.

Merry Life Biomedical has launched a global Phase II clinical trial for TML-6, the first drug targeting the autolysosome pathway for Alzheimer's disease treatment.

• The U.S. healthcare contract research organization market is expected to grow from $15.01 billion in 2025 to $29.68 billion by 2034, driven by increasing R&D investments and technological advancements. • Artificial intelligence integration is revolutionizing CRO operations through enhanced clinical trial design, automated data management, and improved patient recruitment, significantly boosting efficiency and productivity. • The preclinical CRO segment is projected to reach $4.66 billion by 2034, with an 8.2% CAGR, as pharmaceutical companies increasingly outsource specialized research services to reduce costs and accelerate drug development.

Clinical trial sites are struggling with technological overload, with 60% of sites managing over 20 overlapping software systems, creating significant administrative burden for investigators.

Syneos Health successfully integrated 20/20 Onsite's Mobile Clinical Suite to conduct comprehensive eye safety assessments for over 65 patients in a Phase 1 clinical trial.

• The U.S. cell and gene therapy bioanalytical testing services market is projected to grow from $181.73 million in 2025 to $349.29 million by 2034, representing a CAGR of 7.53%. • Bioavailability and bioequivalence studies currently dominate the market with a 33.4% share, while gene-modified cell therapy is expected to be the fastest-growing segment at 7.8% CAGR. • Technological advancements, including AI integration, next-generation sequencing, and mass spectrometry, are transforming testing capabilities and driving market expansion.

Syneos Health is hosting a forward-looking webinar on January 28th exploring emerging healthcare trends, focusing on digital health, biotechnology advances, and personalized medicine solutions.

• The global clinical trial outsourcing market is projected to grow from $43.1 billion in 2025 to $91.2 billion by 2034, representing a robust CAGR of 7.46% as pharmaceutical companies increasingly rely on CROs to streamline research processes. • Advanced technologies including AI, machine learning, and blockchain are transforming clinical trial management, enhancing efficiency and accelerating drug approvals while creating new opportunities for market participants. • North America dominates the market due to its strong pharmaceutical industry and favorable regulatory environment, while Asia-Pacific is emerging as a high-growth region offering cost advantages and large patient populations.

The FDA has cleared CytoDyn's phase 2 trial of leronlimab in relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).

CytoDyn has received FDA clearance to begin a Phase II oncology trial evaluating leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.